Ashkon Software

   







 

IPCI - Intellipharmaceutics International Inc.


IPCI Stock Chart

IPCI Profile

Intellipharmaceutics International Inc. logo

Intellipharmaceutics International Inc. (IPCI) is a pharmaceutical company that develops and commercializes novel and generic controlled-release and targeted-release oral solid dosage drugs. The company uses its proprietary Hypermatrix technology to create controlled-release drug delivery systems.

IPCI has a portfolio of generic drug products, which includes both extended-release and immediate-release versions of well-known branded drugs. In addition to its generic portfolio, the company has a number of drug candidates in various stages of development, including Rexista, a novel, abuse-deterrent oxycodone formulation designed to discourage common methods of abuse.

The company's Hypermatrix technology is a platform for the creation of controlled-release drug delivery systems, which are designed to release drugs over a specific period of time. This technology can be used to create a wide range of drug delivery systems, including matrix tablets, capsules, and osmotic systems.

IPCI has partnerships with several pharmaceutical companies to develop and commercialize its drug products. The company also has a licensing agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic versions of certain drugs.

In recent years, IPCI has faced some challenges related to the commercialization of its drug products. In particular, the company has faced delays and obstacles related to the approval and commercialization of its Rexista drug candidate. However, the company has continued to pursue the development and commercialization of its drug products, and has expressed confidence in the potential of its Hypermatrix technology platform.

Overall, IPCI is a pharmaceutical company that is focused on the development and commercialization of controlled-release and targeted-release oral solid dosage drugs, using its proprietary Hypermatrix technology platform. While the company has faced some challenges in recent years, it continues to pursue the development and commercialization of its dru



 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer